BIOMARIN PHARMACEUTICAL INC — fact timeline

BIOMARIN PHARMACEUTICAL INC reported the first quarter ended March 31, 2026 results: revenue $766 million, net income $106 million. Guidance raised.

“Total Revenues for the first quarter of 2026 were $766 million”

BIOMARIN PHARMACEUTICAL INC incurred credit facility of $2.0 billion senior secured term loan "B" facility, $800.0 million senior secured term loan "A" facility, and $600.0 mil with Citibank, N.A., as administrative agent and collateral agent at Term SOFR plus an applicable margin; for Term B Loans, 1.75% per annum for Term maturing Term Loan B Facility matures on seventh anniversary of Closing Date; Term Loan A Facility and Revolving Facility each mature on fifth anniversary of Closing Dat.

“as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectively). The Credit Agreement provides for a $2.0 billion senior secured term loan “B” facility (the “ Term Loan B Facility ” and the loans thereunder, the “ Term B Loans ”), a $800.0 million senior secured term loan “A” facility (the “”

BIOMARIN PHARMACEUTICAL INC entered into Merger Agreement with Amicus valued at Amicus merged with and into Merger Sub with Amicus continuing as the surviving corporation and as a (effective 2026-04-27).

“ursuant to the terms of the Merger Agreement, Amicus merged with and into Merger Sub (the “ Merger ”) with Amicus continuing as the surviving corporation and as a wholly owned subsidiary of BioMarin.”

BIOMARIN PHARMACEUTICAL INC incurred senior notes of $850 million aggregate principal amount at 5.500% maturing 2026.

“On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.”

BIOMARIN PHARMACEUTICAL INC entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $850 million aggregate principal amount (effective 2026-02-12).

“On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.”

Timothy P. Walbert was appointed as Director at BIOMARIN PHARMACEUTICAL INC.

“the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.”

Greg Friberg was appointed as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.

“He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.”

Henry J. Fuchs retired as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.

“On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).”

BIOMARIN PHARMACEUTICAL INC announced a restructuring with charges of approximately $15 - $20 million affecting research and development programs (approximately 170 employees).

“In connection with the discontinuation of certain research and development programs, on May 9, 2024, the Company committed to a plan to reduce its global workforce by approximately 170 employees. The Company estimates that it will incur aggregate pre-tax charges of approximately $15 - $20 million during the second quarter of 2024, representing one-time cash expenditures for severance and other employee termination benefits.”